By Dr Mark William Donoghoe

Journal articles

Tarnow-Mordi W; Stenson B; Kirby A; Juszczak E; Donoghoe M; Deshpande S; Morley C; King A; Doyle LW; Fleck BW; Davis PG; Halliday HL; Hague W; Cairns P; Darlow BA; Fielder AR; Gebski V; Marlow N; Simmer K; Tin W; Ghadge A; Williams C; Keech A; Wardle SP; Kecskes Z; Kluckow M; Gole G; Evans N; Malcolm G; Luig M; Wright I; Stack J; Tan K; Pritchard M; Gray PH; Morris S; Headley B; Dargaville P; Simes RJ; Brocklehurst P, 2016, 'Outcomes of two trials of oxygen-saturation targets in preterm infants', New England Journal of Medicine, 374, pp. 749 - 760, http://dx.doi.org/10.1056/NEJMoa1514212

Donoghoe MW; Marschner IC, 2015, 'Flexible regression models for rate differences, risk differences and relative risks', International Journal of Biostatistics, 11, pp. 91 - 108, http://dx.doi.org/10.1515/ijb-2014-0044

Darlow BA; Marschner SL; Donoghoe M; Battin MR; Broadbent RS; Elder MJ; Hewson MP; Meyer MP; Ghadge A; Graham P; McNeill NJ; Kuschel CA; Tarnow-Mordi WO, 2014, 'Randomized controlled trial of oxygen saturation targets in very preterm infants: Two year outcomes', Journal of Pediatrics, 165, pp. 30 - e2, http://dx.doi.org/10.1016/j.jpeds.2014.01.017

Donoghoe MW; Marschner IC, 2014, 'Stable computational methods for additive binomial models with application to adjusted risk differences', Computational Statistics and Data Analysis, 80, pp. 184 - 196, http://dx.doi.org/10.1016/j.csda.2014.06.019

Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359

Stenson BJ; Tarnow-Mordi WO; Darlow BA; Simes J; Juszczak E; Askie L; Battin M; Bowler U; Broadbent R; Cairns P; Davis PG; Deshpande S; Donoghoe M; Doyle L; Fleck BW; Ghadge A; Hague W; Halliday HL; Hewson M; King A; Kirby A; Marlow N; Meyer M; Morley C; Simmer K; Tin W; Wardle SP; Brocklehurst P, 2013, 'Oxygen saturation and outcomes in preterm infants', New England Journal of Medicine, 368, pp. 2094 - 2104, http://dx.doi.org/10.1056/NEJMoa1302298

Chan KH; O’Connell RL; Sullivan DR; Hoffmann LS; Rajamani K; Whiting M; Donoghoe MW; Vanhala M; Hamer A; Yu B; Stocker R; Ng MKC; Keech AC, 2013, 'Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study', Diabetologia, 56, pp. 724 - 736, http://dx.doi.org/10.1007/s00125-012-2818-4

Stanton K; Rao S; Assimes T; Wang B; McGee S; Harada R; Wilson A; Narasimhan B; Donoghoe M; Olin J; Cooke J; Ng M, 2012, 'Asymmetric Dimethylarginine (ADMA) Levels Correlate with Peripheral Vascular Disease Severity but not Coronary Artery Disease', Heart, Lung and Circulation, 21, pp. S11 - S11, http://dx.doi.org/10.1016/j.hlc.2012.05.034

Ting R; Keech A; Drury P; Donoghoe M; Hedley J; Jenkins AJ; Davis T; Lehto S; Celermajer DS; Simes J; Kushwin R; Stanton K; Suranyi MG, 2012, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment', Diabetes Care, 35, pp. 218 - 225, http://dx.doi.org/10.2337/dc11-1109

Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TME; Colman PG; Manning P; Fulcher G; Keech AC, 2011, 'Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial', Cardiovascular Diabetology, 10, http://dx.doi.org/10.1186/1475-2840-10-102

Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A, 2011, 'Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study', Diabetes Research and Clinical Practice, 94, pp. 284 - 290, http://dx.doi.org/10.1016/j.diabres.2011.07.028

Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E, 2011, 'Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial', Gynecologic Oncology, 122, pp. 226 - 232, http://dx.doi.org/10.1016/j.ygyno.2011.04.019

Davis TME; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC, 2011, 'Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', Diabetologia, 54, pp. 280 - 290, http://dx.doi.org/10.1007/s00125-010-1951-1

Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497

Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140

Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 219, http://dx.doi.org/10.1016/S1567-5688(10)71044-8

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3

Back to profile page